These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 16193836

  • 1. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
    Yao Y, Kubota T, Takeuchi H, Sato K.
    Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
    [Abstract] [Full Text] [Related]

  • 2. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S, Zarkovic K, Eskinja N, Jonjic N.
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [Abstract] [Full Text] [Related]

  • 3. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
    Miyata Y, Mitsunari K, Asai A, Takehara K, Mochizuki Y, Sakai H.
    Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody.
    Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H.
    Clin Cancer Res; 2001 Nov; 7(11):3410-5. PubMed ID: 11705856
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
    Netto GC, Bleil CB, Hilbig A, Coutinho LM.
    Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
    [Abstract] [Full Text] [Related]

  • 6. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA.
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [Abstract] [Full Text] [Related]

  • 7. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
    Miyata Y, Sagara Y, Watanabe S, Asai A, Matsuo T, Ohba K, Hayashi T, Sakai H.
    Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
    [Abstract] [Full Text] [Related]

  • 8. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
    Sakurai T, Okumura H, Matsumoto M, Uchikado Y, Owaki T, Kita Y, Setoyama T, Omoto I, Kijima Y, Ishigami S, Natsugoe S.
    Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
    [Abstract] [Full Text] [Related]

  • 9. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
    Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA.
    APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
    [Abstract] [Full Text] [Related]

  • 10. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas.
    Barresi V, Cerasoli S, Vitarelli E, Tuccari G.
    Acta Neuropathol; 2007 Aug; 114(2):147-56. PubMed ID: 17594108
    [Abstract] [Full Text] [Related]

  • 11. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
    Raica M, Cimpean AM, Anghel A.
    Neoplasma; 2007 Aug; 54(4):278-84. PubMed ID: 17822316
    [Abstract] [Full Text] [Related]

  • 12. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.
    Yang LY, Lu WQ, Huang GW, Wang W.
    BMC Cancer; 2006 May 02; 6():110. PubMed ID: 16650286
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Microvessel density assessment in benign and malignant endometrial changes.
    Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska-Korczala K.
    J Physiol Pharmacol; 2008 Sep 02; 59 Suppl 4():45-51. PubMed ID: 18955753
    [Abstract] [Full Text] [Related]

  • 15. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
    Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP.
    Gynecol Oncol; 2009 Mar 02; 112(3):583-9. PubMed ID: 19110305
    [Abstract] [Full Text] [Related]

  • 16. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP, Pannain VL.
    World J Gastroenterol; 2015 Jun 14; 21(22):6924-30. PubMed ID: 26078569
    [Abstract] [Full Text] [Related]

  • 17. Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.
    Krishna Priya S, Kumar K, Hiran KR, Bindhu MR, Nagare RP, Vijaykumar DK, Ganesan TS.
    Int J Clin Oncol; 2017 Feb 14; 22(1):107-117. PubMed ID: 27567920
    [Abstract] [Full Text] [Related]

  • 18. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
    Bodey B, Bodey B, Siegel SE, Kaiser HE.
    Anticancer Res; 1998 Feb 14; 18(3A):1485-500. PubMed ID: 9673360
    [Abstract] [Full Text] [Related]

  • 19. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
    Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S.
    Br J Cancer; 2003 May 06; 88(9):1424-31. PubMed ID: 12778073
    [Abstract] [Full Text] [Related]

  • 20. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
    Taskiran C, Erdem O, Onan A, Arisoy O, Acar A, Vural C, Erdem M, Ataoglu O, Guner H.
    Int J Gynecol Cancer; 2006 May 06; 16(5):1789-93. PubMed ID: 17009973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.